Atoderm Ulei de duş

• The Skin Barrier Therapy TM patent biologically prevents attaching of staphylococcus aureus on atopic skin ⁽¹⁾
• High power of hydration (+26%)* ⁽¹⁾
• Skin barrier restructuring (-12% in TEWL) ^{(a) (3)} 

Good cutaneous and ocular tolerance – Pleasant texture – Non-greasy – Non-sticky ^(4.5)

Clinically tested on patients with dry and sensitive skin and paediatric population ⁽¹⁾

* p≤0.001, Student Test, after 27 days

(a) Trans-Epidermal Water Loss. The lower it is, the more it means that water is retained in the skin and therefore that the barrier function is good.

(1)In vivo evaluation of the effectiveness of a sucroester in preventing the adhesion of S. aureus to human corneocytes 
(2)Evaluation of cutation hydration rate of Atoderm Huile de Douche – 52 volunteers (aged 20 – 70 years old) with dry skin on the forearms. France.
(3)In vivo evaluation of reduction in transepidermal water loss (TEWL) of Atoderm Huile de Douche – 11 patients (aged 20 – 59 years old) with dry skin on the forearms with twice application. France
(4)User test on Atoderm Huile de Douche under paediatric population – 15 patients (aged 3 – 36 months) with dry and sensitive skin with only one application. France.
(5)User test on Atoderm Huile de Douche under dermatological and ophthalmological supervision – 21 patients (aged 18 – 70 years old) with dry to very dry skin on the face and body and sensitive and/or reactive skin on the face or body with one or twice application. France

> CLINICAL RESULTS

GENERALITIES
Effectiveness of Atoderm Huile de Douche is also provided by Skin Barrier Therapy TM patent.

 This patent contains sugar esters that regulate the skin flora. Thanks to their structure and surface-active properties, sucroesters can act in different ways to prevent the adhesion of S. aureus :

• A non-specific interface action, such as disrupting the bacterial membrane especially at the attachment systems
• Specific biological action by interacting with or saturating one or several adhesins on S. aureus and/or the corneocytes of the stratum corneum, thereby preventing their adhesion.
   

A clinical study was realized to evaluate the Skin Barrier TherapyTM anti-adhesion effect of staphylococcus aureus on the skin. The results showed that after applying the bacterial suspension, the average found was 276 bacteria per field. Lastly, in the presence of the polysorbate, the number of adherent bacteria decreases significantly by -57%* ⁽¹⁾

After 27 days of Atoderm Huile de Douche application, the hydration power was evaluated by corneometry and the result demonstrated an increase in hydration level (+26%*) ⁽²⁾
Moreover, the restructuring of skin barrier was mesured and after 27 days of application the results showed a significant reduction in TEWL by -12%* ^(3)(a)
The hydration and protection efficacy of Atoderm Huile de douche and Atoderm Intensive Baume in association was evaluated: after 21 days results demonstrated a significant TEWL(a) decrease (-21%)*^(a) reflecting a protective effect. Moreover, this association also induced a significant increase in the skin’s hydration level of (+93%*) ⁽⁴⁾

TOLERANCE
Ocular and cutaneous tolerance of Atoderm Huile de Douche were evaluated as very good ^(5.6)* 

p≤0.001, Student Test, after 27 days

(a) TEWL: Trans Epidermal Water Loss. The lower it is, the more water remains in the skin and therefore the barrier function of the skin is important.

> PATIENTS FEEDBACKS
100% of patients thought that skin is comfortable and satiny immediately after application. The skin is nourished and soothed. ⁽⁵⁾
After 24 hours of application, 80% of patients found that the product reduced itching sensations ⁽⁶⁾

(1) In vivo evaluation of the effectiveness of a sucroester in preventing the adhesion of S. aureus to human corneocytes 
(2) Evaluation of cutation hydration rate of Atoderm Huile de Douche – 52 volunteers (aged 20 – 70 years old) with dry skin on the forearms. France.
(3) In vivo evaluation of reduction in transepidermal water loss (TEWL) of Atoderm Huile de Douche – 11 patients (aged 20 – 59 years old) with dry skin on the forearms with twice application. France
(4) Evaluation of the hydration and protection efficacy of Atoderm Huile de Douche and Atoderm Intensive – 11 patients (aged 21 – 62 years old) with dry to very dry skin on the body during winter with only one application and twice application respectively. France
(5) User test on Atoderm Huile de Douche under paediatric population – 15 patients (aged 3 – 36 months) with dry and sensitive skin with only one application. France.
(6) User test on Atoderm Huile de Douche under dermatological and ophthalmological supervision – 21 patients (aged 18 – 70 years old) with dry to very dry skin on the face and body and sensitive and/or reactive skin on the face or body with one or twice application. France